Several funding options are available through Fast Forward, facilitated by Request For Proposal (RFP) cycles. Specific and rolling RFP's are accepted for review on the following schedule.
Funding available for neuroprotection and neuroregeneration in multiple sclerosis
The National Multiple Sclerosis Society is committed to being a driving force of MS research and treatment to stop disease progression, restore function, and end MS forever.
As part of its commitment to addressing the needs of individuals affected by progressive forms of MS, the Society invites proposals from commercial organizations to establish research partnerships with Fast Forward to accelerate and support development of therapeutic strategies for protecting the nervous system from damage (neuroprotection) and ways to repair the nervous system to restore function.
Note: Inquiries with Fast Forward staff are required to determine alignment of a proposal with Fast Forward's priorities.
The 2012 RFP cycle for the General Fund is closed. Please check back periodically for funding opportunities in 2013.
Accelerating Commercial Development Fund: Provides funding opportunities of up to $500,000 annually (direct and indirect costs) to commercial entities for the development of MS treatments. Funding availability is world-wide, and follows an annual RFP cycle.
To learn more about who has already received funding through the Accelerating Commercial Development Fund, click here.
Accelerating Innovation Fund: Provides funding opportunities of up to $250,000 annually (direct and indirect costs) for university-based or seed-stage organizations. Funding availability is world-wide, and follows an annual RFP cycle.
To learn more about who has already received funding through the Accelerating Innovation Fund, click here.